Peptide Therapeutics Global Market Analysis 2024


The Global Peptide Therapeutics Market is projected to reach $56.52 billion by 2028, from a value of $34.64 billion in 2022, by registering a CAGR of 8.5% during the forecast period 2022 – 2028

SKU: ER1096 Category:
© Epson Research 2021
Share this infographic on
Published Year:
Forecast period:
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Peptide Therapeutics Market is projected to reach $56.52 billion by 2028, from a value of $34.64 billion in 2022, by registering a CAGR of 8.5% during the forecast period. The rising incidence of cancer as well as metabolic disorders, rising healthcare spending and increased federal government healthcare spending, and, advancements in peptide manufacturing technology, are the major factors propelling the growth of the market. However, the production of peptides on a large scale with the increasing complexities of peptides and the high cost of peptide drugs are hampering the market growth. Moreover, the rise in focus on research & development and, the growing adoption of hybrid technologies, are creating ample opportunities across the globe.

Recent Developments

In May 2021, ISSAR Pharmaceuticals announced that it took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.

In December 2019, CohBar, Inc. announced new preclinical data that confirmed the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis (IPF).

In August 2019, Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc signed an agreement with an aim to develop and commercialize Computationally-designed protein therapeutics to address significant unmet medical needs in immuno-oncology, inflammation, and autoimmunity.

In July 2019, Xenetic Biosciences, Inc. acquired novel CAR T (“Chimeric Antigen Receptor T Cell”) platform technology, called “XCART,” designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.

Competitive Landscape

Xenetic Biosciences, Inc, Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc, Novo Nordisk A/S, Novartis AG, Merck & Co, Lonza Inc, ISSAR Pharmaceuticals, GlaxoSmithKline (GSK), Eli Lilly and Company, Bristol-Myers Squibb(BMS), Bachem Holding AG, AstraZeneca PLC, Amgen Inc, Aquinox Pharmaceuticals, Inc., ISSAR Pharmaceuticals, CohBar, Inc are some of the major players in the Global Peptide Therapeutics Market.


1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Peptide Therapeutics Market by Type
5.1 Branded
5.2 Generic
5.3 Innovative
6 Peptide Therapeutics Market by Type of Molecule
6.1 Calcitonin
6.2 Glucagon and Analogs
6.3 Immunopeptide
6.4 Insulins
6.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
6.6 Natriuretic
6.7 Somatostatin
6.8 Vasopressin
7 Peptide Therapeutics Market by Type of Manufacturer
7.1 Contract Manufacturing Organizations (CMOs)
7.2 In-house
7.3 Outsourced
8 Peptide Therapeutics Market by Route of Administration
8.1 Injection
8.2 Mucosal
8.3 Oral
8.4 Parenteral
8.5 Pulmonary
8.6 Other Route of Administrations
8.6.1 Intradermal
8.6.2 Nasal
9 Peptide Therapeutics Market by Synthesis Technology
9.1 Hybrid Technology
9.2 Liquid Phase Peptide Synthesis (LPPS)
9.3 Solid Phase Peptide Synthesis (SPPS)
10 Peptide Therapeutics Market by Application
10.1 Acromegaly
10.2 Anti-infection
10.3 Cancer
10.3.1 Zoladex (Goserelin)
10.3.2 Velcade (Bortezomib)
10.3.3 Lupron/ Enantone/ Eligard (Leuprorelin)
10.4 Cardiovascular Disorder
10.4.1 Integrilin (Eptifibatide)
10.4.2 Angiomax (Bivalirudin)
10.5 Central Nervous System (Copaxone (Glatiramer))
10.6 Dermatology
10.7 Gastro-Intestinal Infection (GIT)
10.7.1 Gattex (Teduglutide)
10.7.2 Linzess (Linaclotide)
10.8 Hematological Disorders
10.8.1 Kalbitor (Ecallantide)
10.8.2 Firazyr (Icatibant)
10.9 Infection
10.9.1 Incivek (Telaprevir)
10.9.2 Victrelis (Boceprevir)
10.10 Metabolic
10.10.1 Byetta (Exenatide)
10.10.2 Victoza (Liraglutide)
10.11 Respiratory
10.12 Renal
10.13 Pain
10.14 Other Applications
10.14.1 Allergy/Immunological
10.14.2 Osteoporosis
11 Peptide Therapeutics Market by End User
11.1 Pharmaceutical and Biotechnology Industries
11.2 Hospitals
11.3 Contract Research Organization
11.4 Academic and Research Institutes
12 Peptide Therapeutics Market by Regions
12.1 North America
12.2 Europe
12.3 Asia Pacific
12.4 Rest of the World
13 Company Profiles
13.1 Xenetic Biosciences, Inc
13.2 Takeda Pharmaceutical Company Limited
13.3 Sanofi
13.4 Pfizer Inc
13.5 Novo Nordisk A/S
13.6 Novartis AG
13.7 Merck & Co
13.8 Lonza Inc
13.9 ISSAR Pharmaceuticals
13.10 GlaxoSmithKline (GSK)
13.11 Eli Lilly and Company
13.12 Bristol-Myers Squibb(BMS)
13.13 Bachem Holding AG
13.14 AstraZeneca PLC
13.15 Amgen Inc
13.16 Aquinox Pharmaceuticals, Inc.
13.17 ISSAR Pharmaceuticals
13.18 CohBar, Inc